^
    over2years
    BET and CDK Inhibition Reveal Differences in the Proliferation Control of Sympathetic Ganglion Neuroblasts and Adrenal Chromaffin Cells. (PubMed, Cancers (Basel))
    However, differential effects were observed in response to bromodomain and extraterminal (BET) protein inhibitors (JQ1, GSK1324726A) and to the CDK-7 inhibitor THZ1, with BET inhibitors preferentially affecting chromaffin cells, and THZ1 preferentially affecting neuroblasts. The differential dependence of chromaffin cells and neuroblasts on BET and CDK signaling may indicate different mechanisms during tumor initiation in sympathetic ganglia and adrenal.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • IGF1 (Insulin-like growth factor 1) • CDK7 (Cyclin Dependent Kinase 7)
    |
    JQ-1 • GSK1324726A
    3years
    Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. (PubMed, Melanoma Res)
    Cultured B16F10 cells and human UM cells were treated with the histone deacetylase inhibitor (HDACi) entinostat or BETi JQ1...Co-treatment with the bioavailable BETi iBET726 impaired the immunotherapy effect...Indeed, co-cultures of UM with HLA-matched melanoma-specific tumor-infiltrating lymphocytes (TILs) resulted in higher TIL-mediated melanoma killing when entinostat was added. Further exploration of combined immunotherapy and epigenetic therapy in metastatic melanoma resistant to PD-1 inhibition is warranted.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    JQ-1 • Jingzhuda (entinostat) • GSK1324726A